Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: better (427), enhanced (152), superior (12)

Sleep hygiene - patient information

Description: This factsheet explains what sleep hygiene is, why it is so important and what you can do to help improve the
Url: /Media/UHS-website-2019/Patientinformation/Other/Sleep-hygiene-3276-PIL.pdf

Atezolizumab-Bevacizumab

Description: Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with bevacizumab for the first-line systemic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information contact: Chris Stock Head of R&D communications
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Pembrolizumab_400mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untreated PD-L1 positive metastatic non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description: Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untreated PD-L1 positive metastatic non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Pembrolizumab_400mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

81 to 90 of 762

Previous … 7 8 9 10 11 … Next